First-half results: net sales 17.56 hundred million yen, operating income 1.55 hundred million yen, ordinary income 3.08 hundred million yen, net income attributable to owners of parent 2.19 hundred million yen. Achieved significant year-over-year revenue and profit growth. Order timing shifts in CRO non-clinical and cost timing adjustments in the TR business were contributing factors. Full-year FY2027 forecast was also raised, indicating improved utilization in research-related businesses and progress on new projects.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2395","jir_company_name":"Shin Nippon Biomedical Laboratories, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2395-20261110-02.pdf","jir_short_summary":"First-half results: net sales 17.56 hundred million yen, operating income 1.55 hundred million yen, ordinary income 3.08 hundred million yen, net income attributable to owners of parent 2.19 hundred million yen. Achieved significant year-over-year revenue and profit growth. Order timing shifts in CRO non-clinical and cost timing adjustments in the TR business were contributing factors. Full-year FY2027 forecast was also raised, indicating improved utilization in research-related businesses and progress on new projects.","jir_summary":"### Overview of Results\nThe first-half results for the fiscal year ending March 2027 showed net sales of 17.56 hundred million yen (YoY +19.0%), operating income of 1.55 hundred million yen, ordinary income of 3.08 hundred million yen, and net income attributable to owners of parent of 2.19 hundred million yen, representing substantial improvement. Increased orders and sales in both non-clinical and clinical CRO businesses and the deferral of TR business expenses to the second half contributed to profit improvement. Equity in earnings from affiliates such as Shin Nippon Biomedical Laboratories PPD also contributed.\n\n### Outlook and Impact for Investors\nThe full-year FY2027 forecast is expected to be revised upward as contributing factors persist. Growth in the CRO business is anticipated due to stronger orders from clients in Europe and the U.S., and expansion of the TR business including Atzumi is expected to progress. Although some expense deferral to the second half may continue, overall the company plans to strengthen its long-term growth foundation through allocation of capital expenditures and R&D spending.","jir_financial_highlights":"Net Sales (First Half): 175.6 (YoY +19.0%)\nOperating Income: 15.5 (More than 1000% increase YoY)\nOrdinary Income: 30.8 (Significant YoY increase)\nNet Income Attributable to Owners of Parent: 21.9 (YoY +107.1%)\nSegment Contributions: CRO Business (Non-clinical) \/ CRO Business (Clinical) \/ TR Business \/ Medipolis, etc. (Contributed to overall revenue and profit increase in the first half)","jir_category":"","jir_hashtags":"#ShinNipponBiomedical Laboratories, #Earnings, #BusinessHighlights, #CRO, #TRBusiness","jir_key_figures":"Net Sales First Half 17.56 hundred million yen (FY2026 First Half actual)\nOperating Income First Half 1.55 hundred million yen\nOrdinary Income First Half 3.08 hundred million yen\nNet Income Attributable to Owners of Parent First Half 2.19 hundred million yen\nFY2027 Full-Year Forecast Includes First Half Results","jir_meta_title":"Shin Nippon Biomedical Laboratories, Ltd. \u2014 First Half Results for FY2027 and Outlook","jir_meta_description":"Key points of Shin Nippon Biomedical Laboratories, Ltd.'s first-half results for FY2027: revenue and profit performance, segment trends, and full-year outlook summarized for investors.","jir_og_title":"Key Points and Outlook of Shin Nippon Biomedical Laboratories, Ltd.'s First Half Results","jir_og_description":"Shin Nippon Biomedical Laboratories, Ltd. reported year-over-year revenue and profit growth in the first half. Analysis of CRO and TR business trends and the full-year outlook to support investment decisions.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 First Half\\\",\\\"FY2027 First Half\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[175.6, - ]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 First Half\\\",\\\"FY2027 First Half\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[15.5, - ]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{ \\\"labels\\\":[\\\"CRO Non-clinical\\\",\\\"CRO Clinical\\\",\\\"TR\\\",\\\"Medipolis\\\"],\\\"datasets\\\":[{}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{ \\\"labels\\\":[\\\"Operating Margin\\\",\\\"Ordinary Income Margin\\\"],\\\"datasets\\\":[]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Comparison of Forecasts and Results\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":{}}\"}]","ir_related_company":17048,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-145946","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n